tbuckley/cabot-search huggingface dataset:
Abstract 523: Pioglitazone and Glucagon-like Peptide 1 Receptor Agonist Stimulate Mitochondrial Turnover in the Heart When Administered After the Infarct in Obese Mice
Authors: Allen M Andres, Allen M Andres, Juliana Germano, Chengqun Huang, Kyle C Tucker, Yang Song, Jon Sin, Roberta A Gottlieb, Robert M Mentzer
Journal: Circulation Research (2018)

Randomized clinical trials have demonstrated that pioglitazone (PIO), a thiazolidinedione, and liraglutide and semaglutide, glucagon-like peptide-1 receptor agonists (GLP1Ra), are effective in treating Type 2 diabetes mellitus. Of considerable interest is the additional observation that they may also be effective in reducing the incidence of major adverse cardiovascular events (MACE) independent of glycemic control. The mechanism underlying this protection is unknown. To test the hypothesis that enhanced mitochondrial turnover (mitophagy and mitochondrial biogenesis) might play a role, obese mice with insulin resistance were subjected to permanent coronary artery ligation (PCAL). Two hours later they were administered an i.p. bolus of vehicle (50μL DMSO), PIO (10mg/kg), or a GLP1Ra (10nmoles/25g) (Sigma). This was repeated every other day for 2 weeks. Hearts were probed by western blot for markers of mitochondrial biogenesis and mitophagy. As shown, PIO was a strong inducer of mitochondrial biogenesis evidenced by increased mitochondrial markers in the whole lysate (mitochondrial biogenesis) whereas GLP1Ra stimulated mitophagy, indicated by Parkin, p62 and optineurin translocation to the mitochondrial fraction. These findings suggest that enhanced mitochondrial biogenesis and mitophagy may be important therapeutic targets for the prevention of adverse cardiovascular outcomes. If confirmed, enhanced mitochondrial turnover may be one of the mechanisms underlying the reduced incidence of MACE that was observed in the PROactive (PIO) and the LEADER and SUSTAIN-6 (GLP1Ra) clinical trials.
THE ROLE OF SERUM CARDIAC BIOMARKERS AND LEFT VENTRICULAR STRAIN IMAGING FOR DETECTING EARLY RADIATION INDUCED MYOCARDIAL DAMAGE IN WOMEN UNDERGOING LEFT-SIDED BREAST RADIATION THERAPY: A PILOT STUDY
Authors: Alexandra Murphy, Omar Farouque, Anoop Koshy, Farshad Faroudi, Mark Horrigan, Michael Chao, Terase Lancefield
Journal: Journal of the American College of Cardiology (2019)
Abstract 222: Estrogen Protects Artery From Senescence via Sirt1/AMPK/Rab9—Mediated Mitophagy
Authors: Yuichi Sasaki, Yoshiyuki Ikeda, Yuichi Akasaki, Yoshihiro Uchikado, Mitsuru Ohishi
Journal: Circulation Research (2018)

Background: Estrogen protects artery from senescence. Mitochondria plays a crucial role to regulate cellular senescence. Recently it is reported that mitochondria undergo quality control by mitochondria-targeted autophagy, referred to as mitophagy. This study aims to examine whether estrogen modulates mitophagy, and to clarify the potential mechanism. Methods and Results: We used HUVEC and vascular smooth muscle cells. Estradiol treatment (E2) decreased the protein expressions of p21 and p53, senescence-associated beta galactosidase activity, ubiquitinated and depolarized mitochondria, and reactive oxygen species production compared to untreated-control cells, suggesting that estrogen maintains mitochondrial function and retards cellular senescence. E2 significantly increased the number of autophagy formation assessed by electron microscopy and Lamp2 puncta which co-localized with TOMM20 assessed by Immunohistochemistry, suggesting that E2 induces mitophagy. E2 did not moderate the ratio of LC3II/LC3I, whereas upregulated membrane trafficking protein Rab9 expression. The number of Rab9 puncta significantly increased and co-localized with Lamp2 puncta in E2-treated cells. The effects of E2 on increasing autophagy, maintaining mitochondrial function and retarding cellular senescence were abolished by knock-down of Rab9. Taken together, these results suggest that E2-mediated mitophagy was derived from Rab9-dependent alternative autophagy. E2 upregulated protein expression of Sirt-1 and AMPK activity. Administration of either Sirt-1 inhibitor, sirtinol, or AMPK inhibitor, compound c, abrogated upregulation of Rab9 and induction of mitophagy. These results indicate that the effect of E2 on inducing Rab9 is mediated by Sirt-1/AMPK pathway. Finally, we performed in vivo experiment. Apolipoprotein E knockout mouse (ApoE-KO) with ovariectomy showed lower number of autophagy formation, mitochondrial function, and Rab9 expression compared to ApoE-KO with sham operation. Conclusion: Mitophagy derived from Sirt1/AMPK/Rab9-mediated mitophagy plays a key role in the effect of estrogen on retarding vascular senescence.
PREDICTIVE VALUE OF RIGHT VENTRICULAR MECHANICS ON POSTOPERATIVE RIGHT VENTRICULAR FUNCTION IN PATIENTS UNDERGOING MITRAL VALVE SURGERY
Authors: Marton Tokodi, Balint K. Lakatos, Erika Kispal, Kristof Racz, Adam Soltesz, Istvan Hartyanszki, Endre Nemeth, Attila Kovács, Bela Merkely
Journal: Journal of the American College of Cardiology (2019)
Platelet Features from Immune Thrombocytopenia Patients Refractory to Therapeutic Treatments
Authors: Raul Justo Sanz, Teresa Álvarez-Roman, Mónica Martín, Elena Monzón Manzano, Ihosvany Fernandez-Bello, María Isabel Rivas Pollmar, Gonzalo Carreño Gomez-Tarragona, Miguel A. Canales, Victor Jimenez-Yuste, Nora Butta
Journal: Blood (2017)
DNMT3A and NPM1 Double Mutated AML Is a Phenomenon of the Younger Patient and Could Represent a New Entity
Authors: Luca Vincenzo Cappelli, Manja Meggendorfer, Frank Dicker, Sabine Jeromin, Stephan Hutter, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach, Alexander Höllein
Journal: Blood (2018)
TRENDS IN ACUTE POST-ABLATION PERICARDITIS AND RELATED HEALTHCARE BURDEN IN SYMPTOMATIC ATRIAL FIBRILLATION HOSPITALIZATIONS: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2009-2014)
Authors: Sonu Gupta, Rupak Desai, Arnav Kumar, Kimi Sato, Modele Ogunniyi, Nanette Kass Wenger, Gautam Kumar, Rajesh Sachdeva, Allan Klein
Journal: Journal of the American College of Cardiology (2019)
HIGH-SENSITIVITY TROPONIN I AND INCIDENT GLOBAL CARDIOVASCULAR EVENTS IN A COMMUNITY-BASED COHORT: ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY
Authors: Xiaoming Jia, Wensheng Sun, Ron Hoogeveen, Vijay Nambi, Kunihiro Matsushita, Aaron Folsom, Gerardo Heiss, David Couper, Scott Solomon, Eric Boerwinkle, Amil Shah, Elizabeth Selvin, James de Lemos, Christie Ballantyne
Journal: Journal of the American College of Cardiology (2019)
HIV-1 remission achieved in second patient, report UK researchers
Authors: Harriet Pike
Journal: BMJ (2019)

A patient with HIV has achieved remission from infection following a stem cell transplantation, UK researchers have reported in a paper published in Nature .1 It is the second recorded case of patient remission from HIV-1 infection after stem cell transplantation.

Ravindra Gupta, from the University of Cambridge, and colleagues say that the patient has been in remission for 18 months. They warn, however, that it is too early to say that the patient has been “cured.” They conclude that their data suggest that a single …
Factors that may influence the absence of liver metastases in a spontaneous colorectal cancer animal model- Potential targets for intervention in humans
Authors: Martin Tobi, James Hatfield, Michael Kam, Violeta Iordanova, Nabiha Khoury, Neal Clapp, Jason Hallman, Michael J. Lawson, Peter Thomas
Journal: Cancer Research (2004)

1836  Colorectal cancer survival would improve if liver spread could be averted. The cotton top tamarin (CTT) spontaneously develops colorectal cancer but liver metastases are rare. We studied three mechanisms to explain this phenomenon: 1. Pentatpeptide PELPK-encoding nucleotide sequence changes in the N-terminal-A1 hinge region of the CEA molecule, and the effect of Kupffer cell blockade on human serum CEA; 2. Glycosylation changes in the CEA molecule in the tamarin by enzymatic deglycosylation and; 3. We performed immunostaining to determine the distribution of biliary glycoprotein (BGP), also known as CEACAM1 or CD66a, in tamarin (kindly provided by NERPC) and in human livers with and without metastatic disease pre-selected our pathologist. BGP is a putative vascular endothelial growth factor and is recognized by a specific monoclonal antibody (Prall & Wagener et al, 1996). 70% of CTT had changes in somatic PELPK sequences. Cancer animals had higher rates of PELPK changes, specifically in the LP bipeptide (p
RNA-Seq and protein mass spectrometry in microdissected kidney tubules reveal signaling processes initiating lithium-induced nephrogenic diabetes insipidus
Authors: Chih-Chien Sung, Lihe Chen, Kavee Limbutara, Hyun Jun Jung, Gabrielle G. Gilmer, Chin-Rang Yang, Shih-Hua Lin, Sookkasem Khositseth, Chung-Lin Chou, Mark A. Knepper
Journal: Kidney International (2019)
Abstract 9945: Early Ambulation After an Initial Implantable Cardioverter Defibrillator (ICD) is Safe and Efficacious
Authors: Cynthia M Dougherty, Emily T Lau, Robert L Burr, Elainet A Thompson
Journal: Circulation (2015)

Introduction: Early ambulation after hospitalization accelerates return to physical functioning and reduces post-hospital complications. After an ICD, patients are discharged with activity restrictions to prevent lead dislodgement, but evidence-based recommendations for safe exercise are not in place. Methods: Using a single group pre-post design, 225 patients after an initial ICD were prescribed a nurse-monitored home based walking program at hospital d/c and were followed for 3 months. The mild intensity (Borg rating=3) protocol was designed to increase walking from 10 min/day to 30 min/day. Activity progression was monitored by weekly nurse phone calls. Efficacy was measured in total steps/day (Cyma Step Watch™), self-reported exercise (exercise log), and self-efficacy for walking (SEW). ICD shocks and hospitalizations were verified with medical records. ANOVA was used to determine effects on outcomes from baseline to 3 months. Results: Patients were (mean+SD) 64+12 years old, 90% Caucasian, 75% male, EF% 35.7+17.5, having received an ICD for primary (58%) or secondary prevention (42%), with a Charlson score =2.3+1.6. Safety: There were 15 (7.6%) individuals who received 22 ICD shocks, of which 11 were inappropriate for either atrial or supraventricular arrhythmias. There was 1 appropriate ICD shock related to physical activity (elliptical trainer), but none occurred during prescribed home walking. Hospitalization for any cause was 22.8%, with 10(5%) related to ICD shocks, none of which were exercise related. Efficacy: physical activity significantly increased in steps/day (6854+3502 to 7839+4064, p&lt;0.001), exercise times/week (4.2+3.2 to 7.1+4.3, p&lt;0.001), SEW (7.2+2.1 to 8.8+1.5, p&lt;0.001). At 3 months 148/225 (66%) were walking 30 min/day on 4 days/week. Conclusions: A mild intensity early ambulation program following initial ICD implant is safe and is related to increased physical activity and self-efficacy for exercise, without being related to ICD shocks or hospitalizations. The walking protocol offers clinicians an algorithm for incorporating ambulation into activity routines in early post-ICD recovery.
A NEW SIMPLE INDEX FOR PRE-OPERATIVE CARDIOVASCULAR EVALUATION AND RISK STRATIFICATION OF PATIENTS SCHEDULED FOR NON CARDIAC SURGERY: RESULTS OF THE AMERICAN UNIVERSITY OF BEIRUT PRE-OPERATIVE CARDIOVASCULAR EVALUATION STUDY (AUB-POCES)
Authors: Habib A. Dakik, Omar Chehab, Mahmoud Eldirani, Eman Sbeity, Cynthia Karam, Ossama Abou Hassan, Mayyas Msheik, Hussein Hassan, Ahmad Msheik, Chris Kaspar, Maha Makki, Hani Tamim
Journal: Journal of the American College of Cardiology (2019)
Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible
Authors: Torsten Kessler, Steffen Koschmieder, Christoph Schliemann, Martina Crysandt, Jan-Henrik Mikesch, Matthias Stelljes, Linus Angenendt, Georg Lenz, Anna Kirsch, Kerstin Vehring, Hartmann Wolfgang, Eva Wardelmann, Eike Bormann, Joachim Gerss, Tim H. Brümmendorf, Carsten Mueller-Tidow, Wolfgang E. Berdel
Journal: Blood (2018)
Abstract 378: Evaluation of Patient Specific <i>MTERF4</i> Variants in Gene Edited Human iPSC-derived Cardiomyocytes
Authors: Maribel Marquez, Chris McDermott-Roe, Mike Grzybowski, Daniel Helbling, David P Dimmock, James W Verbsky, Aron M Geurts
Journal: Circulation Research (2018)

Mitochondrial Transcription Termination Factor 4 ( MTERF4 ) is a transcription factor involved in mitochondrial ribosomal biogenesis and was identified as a gene of interest via whole exome sequencing in a pediatric patient with hypertrophic cardiomyopathy (HCM) at Children’s Hospital of Wisconsin. The variants of interest identified in MTERF4 have not been previously reported in the literature or associated with HCM. Here, we combined precision genome editing via CRISPR/Cas9 system with human iPSC-derived cardiomyocytes (hiPSC-derived CMs) to model the HCM patient-specific MTERF4 variants. We hypothesize that MTERF4 variants are contributing to cardiomyocyte impairment, leading to the development of the hypertrophic phenotype. To improve our efficiency of CRISPR/Cas9 precision genome editing in hiPSCs, we are using a co-targeting with selection method. MTERF4 mutant clones and control hiPSCs (obtained from co-targeted but unmodified by CRISPR/Cas9) were identified by Sanger sequencing and assessed for pluripotency using immunostaining and gene expression. MTERF4 clones and controls were subjected to our modified Palecek matrix-overlay method for CM differentiation and evaluated at 3-4 weeks for cell size, mitochondrial function, and gene expression. The hiPSC-derived CMs cell size analysis by average pixel area of the MTERF4 mutant indicated that they are significantly (p=0.0012) larger compared to MTERF4 control. The assessment of mitochondrial function demonstrated that the maximal mitochondrial respiration may be reduced in MTERF4 mutant hiPSC-derived CMs compared to control (p=0.056). In known cardiovascular disease genes (NPPA, NPPB, GATA4, TNNT, MYL7, MYH7) associated with HCM, gene expression (qRT-PCR) were elevated. Preliminary data support our hypothesis through changes in CMs size, mitochondrial function, and transcriptional expression for one MTERF4 mutant clone and control. This approach has generated an in vitro tool to evaluate aspects diseases such as cardiomyopathy that can be used for diagnostic screening and therapy. Repeating our initial studies, and adding mechanistic studies, with additional MTERF4 mutant and control clones will further validate our hypothesis.
HEART FAILURE RISK DISTRIBUTION AND TRENDS IN THE UNITED STATES POPULATION FROM 1999-2014: RESULTS FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY
Authors: Peter Glynn, Hongyan Ning, Aakash Bavishi, Sanjiv Shah, Clyde Yancy, Donald Lloyd-Jones, Sadiya Khan
Journal: Journal of the American College of Cardiology (2019)
ASSOCIATIONS BETWEEN BETA-BLOCKER THERAPY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM THE TECOS STUDY
Authors: Jay Shavadia, Yinggan Zheng, Jennifer B. Green, Paul Armstrong, Cynthia Westerhout, Darren McGuire, Matthew Roe, J.H. Cornel, Rury Holman, Eric D. Peterson
Journal: Journal of the American College of Cardiology (2019)
5TH GENERATION HIGH SENSITIVITY TROPONIN ASSAY, INCIDENCE OF ACUTE CORONARY SYNDROME, AND SHORT-TERM MORTALITY: INSIGHT FROM A UNITED STATES EMERGENCY POPULATION
Authors: Deep Shah, Shray Jain, Galen Hayek, Nathan Nahhas, Caroline Lerner, Susan Fuhrman, Anand Gupta, Tamara McMath, Karanvir Grewal
Journal: Journal of the American College of Cardiology (2019)
Abstract #1208: Balance of toxification and detoxification biomarkers of acrylamide in rats at low doses
Authors: Matthias Baum, Franz Ingo Berger, Julia Feld, Gerhard Eisenbrand
Journal: Cancer Research (2009)

Acrylamide (AA) maybe formed in carbohydrate rich foods at substantial rates during thermal processing. It is regarded as a genotoxic carcinogen as a consequence of its biotransformation into glycidamide (GA) through CYP 2E1 mediated epoxide formation. GA is perceived to represent the ultimal genotoxic agent since it may form DNA adducts at N7 of guanine. AA and GA are detoxified via conjugation with glutathione, to be excreted in urine as mercapturic acids. In the present study rats received AA at a dose of 100µg/kg b.w. daily for up to 9 days via drinking water or French fries (AA content: 2800 µg/kg). Urine was collected over 24h after the last AA dosing. Blood samples were taken between 30min and 4h after AA dosing. After 24h animals were sacrificed and blood and liver cells collected. Mercapturic acids from AA (AAMA) and GA (GAMA) were determined in the urine by HPLC/MS/MS. Adducts of AA (AA-Val) and GA (GA-Val) with the N-terminal valine of hemoglobin (Hb) isolated from red blood cells were determined by GC/MS. In peripheral white blood cells and liver cells, potential induction of DNA damage was investigated by the Comet assay. AA and GA in blood plasma and urine were determined by HPLC/MS/MS. As evidenced by the GAMA/AAMA ratio in urine (0.3-1.1), significant amounts of GA were formed after AA uptake. AA-Val adduct levels in Hb reflect the cumulative AA uptake. Under all conditions tested, GA-Val never exceeded background levels of untreated controls. In addition, only trace amounts of GA were found in plasma. These results indicate, that AA and GA at the dose levels tested for 9 consecutive days are efficiently detoxified via GSH conjugation. At best traces of GA generated in the liver reach systemic circulation, too low to have a significant impact on the GA-Val biomarker. Supportive evidence for this interpretation came from the absence of a significant comet response for DNA damage in liver and blood cells. The same results were obtained when the cumulative AA dose of 900 µg/kg was given in a single application. Thus, within the tested dosage range mimicking high end dietary intake up to the exposure level found tumorigenic in long term studies, detoxification pathways appear to predominate. Supported by the German Ministry of Economics and Technology (via AiF), the FEI (Forschungskreis der Ernahrungsindustrie e.V., Bonn) and the BLL (Bund fur Lebensmittelrecht und Lebensmittelkunde e.V.). Project AiF 209 ZGB  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1208.
NATIONAL TRENDS AND IN-HOSPITAL OUTCOMES OF EMERGENT TRANSCATHETER AORTIC VALVE REPLACEMENT AND BALLOON AORTIC VALVULOPLASTY IN PATIENTS WITH SEVERE AORTIC STENOSIS AND CARDIOGENIC SHOCK
Authors: Raviteja Guddeti, Dixitha Anugula, Ryan Walters, Dennis Esterbrooks, Arun Kanmanthareddy
Journal: Journal of the American College of Cardiology (2019)
Association of Long-term Use of Low-Dose Aspirin as Chemoprevention With Risk of Lung Cancer
Authors: Shinhee Ye, Myeongjee Lee, Dongheon Lee, Eun-Hee Ha, Eun Mi Chun
Journal: JAMA Network Open (2019)

Low-dose aspirin use for chemoprevention of lung cancer risk remains controversial.To investigate the association between low-dose aspirin use and lung cancer risk, and to identify specific subgroups that may derive the most benefit from low-dose aspirin use.This nationwide, retrospective, cohort study used data from the Korean National Health Information Database from 2002 to 2015. Data analyses were performed from October 2016 to December 2018. Eligible participants (n = 12 969 400) were people aged 40 to 84 years who had undergone national health screening between 2009 and 2010 and had no history of lung cancer between 2006 and 2010 and no standard-dose aspirin use for 6 months between 2002 and 2010.The duration of low-dose aspirin use between January 2002 and December 2010 was calculated for each participant. Lung cancer was defined as the first recorded diagnosis of lung cancer-using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes and expanding benefit coverage-between January 2011 and December 2015.A total of 63 040 participants with a mean (SD) age of 66.4 (9.3) years received a diagnosis of lung cancer. Of these, 45 156 (71.6%) were men. The incidence rate of lung cancer was 98.8 per 100 000 person-years. The duration of low-dose aspirin use was none for 10 987 417 participants (84.7%), 1 to 2 years for 750 992 participants (5.8%), 3 to 4 years for 506 945 participants (3.9%), 5 to 6 years for 371 062 participants (2.9%), 7 to 8 years for 240 528 participants (1.9%), and 9 years for 112 456 participants (0.9%). Compared with no aspirin use, 5 to 6 years (adjusted hazard ratio, 0.96 [95% CI, 0.92-0.99]), 7 to 8 years (adjusted hazard ratio, 0.94 [95% CI, 0.90-0.99]), and 9 years (adjusted hazard ratio, 0.89 [95% CI, 0.84-0.94]) of aspirin use were significantly associated with reduced lung cancer risk. After stratified analysis, a significant reduction of lung cancer risk was observed among people aged 65 years or older and among people without diabetes.Although the use of low-dose aspirin for more than 5 years was associated with decreased risk of lung cancer, particularly among elderly participants and among people without diabetes, the observed effect size was quite modest. Future prospective studies are needed to determine whether there is a causal association.
PREDICTIVE VALUE OF LEFT VENTRICULAR DIASTOLIC CHAMBER STIFFNESS IN PATIENTS WITH SEVERE AORTIC STENOSIS UNDERGOING AORTIC VALVE REPLACEMENT
Authors: Vidhu Anand, Rosalyn Adigun, Christopher Kane, Patricia Pellikka, Vuyisile Nkomo, Sorin Pislaru, Kevin Greason, Jeremy Thaden, Cristina Pislaru
Journal: Journal of the American College of Cardiology (2019)
NOVEL INTERACTION BETWEEN RIGHT VENTRICULAR FUNCTION AND MYOCARDIAL FIBROSIS IS A POWERFUL PREDICTOR OF OUTCOMES IN PATIENTS WITH NON-ISCHEMIC CARDIOMYOPATHY
Authors: Shailee Y. Shah, Nishant Shah, Sophia Downey, Nathaniel Lee, Scott Flamm, Wai Hong Tang, Brian Griffin, Deborah Kwon
Journal: Journal of the American College of Cardiology (2019)
FETAL CARDIAC INTERVENTION IN AORTIC STENOSIS AND AORTIC ATRESIA WITH SEVERE MITRAL REGURGITATION: A REPORT OF THE INTERNATIONAL FETAL CARDIAC INTERVENTION REGISTRY (IFCIR)
Authors: Marco Rodriguez, Betul Yilmaz, Anita Moon-Grady, Aimee Armstrong, Michele Frommelt, Joanna Dangel, Alberto Galindo, Sofia Grinenco, Monique Haak, Ulrike Herberg, Edgar Jaeggi, Adam Kolesnik, Sophie Malekzadeh-Milani, Pablo Marantz, Owen Miller, Dick Oepkes, Carlos Pedra, Simone Pedra, Athar Qureshi, John Simpson, James Strainic, Shaine Morris
Journal: Journal of the American College of Cardiology (2019)
LINKING THE NCDR CATHPCI REGISTRY WITH ADMINISTRATIVE CLAIMS TO DETERMINE ATTRIBUTION OF REPEAT REVASCULARIZATION FOLLOWING INDEX DRUG-ELUTING STENT IMPLANTATION
Authors: Sanket Shishir Dhruva, Craig Parzynski, Jeptha Curtis, Nihar Desai, Robert Yeh, Frederick Masoudi, Sharon-Lise Normand, Richard Kuntz, Richard Shaw, Danica Marinac-Dabic, Harlan M. Krumholz, Joseph Ross
Journal: Journal of the American College of Cardiology (2019)
Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)
Authors: Murielle Roussel, Benjamin Hebraud, Valerie Lauwers-Cances, Margaret Macro, Xavier Leleu, Cyrille Hulin, Lionel Karlin, Bruno Royer, Aurore Perrot, Philippe Moreau, Denis Caillot, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Brigitte Pegourie, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean Valere Malfuson, Veronique Dorvaux, Pascal Lenain, Omar Benbrahim, Arnaud Jaccard, Cecile Borel, Herve Avet Loiseau, Michel Attal
Journal: Blood (2017)